JNJ.DE Johnson & Johnson
Company Analysis
Latest News
Johnson & Johnson to present 35+ myeloma abstracts, targeting potential cures
Johnson & Johnson will present over 35 abstracts at the 2026 International Myeloma Society (IMS) Annual Meeting. The data includes Phase 3 results and...
Analysis Questions Johnson & Johnson's Dividend Streak Ahead of Planned Spinoff
A recent analysis suggests Johnson & Johnson's celebrated dividend growth streak could face pressure. This pressure stems from the planned spinoff of its DePuy...
🟢 Johnson & Johnson is trading 4.4% up today as healthcare stocks rise 1.37%
Johnson & Johnson is trading at €241.40, up +4.43%, as healthcare stocks rise 1.37% on strong medical-device earnings from Medtronic and MiniMed Group. - No...
J&J Wins FDA Approval for IMAAVY, First Treatment for Rare Blood Disorder
The FDA approved Johnson & Johnson’s IMAAVY (nipocalimab-aahu) for adults and children aged 12 and older with warm autoimmune hemolytic anemia (wAIHA). This...
J&J Wins EU Approval for TECVAYLI Combination, Expanding Early Myeloma Care
Johnson & Johnson received European Commission approval for an expanded indication of TECVAYLI® (teclistamab). The approval authorizes its use in combination...
J&J Lowers 2026 Profit Forecast, Citing Costs From New Biotech Deals
Johnson & Johnson lowered its 2026 adjusted profit forecast to a range of $10.96 to $11.11 per share. This revision marks a decrease from the previous guidance...
🔴 Johnson & Johnson is trading 3.2% down today on €5.5B talc-litigation settlement
Johnson & Johnson is trading 3.2% down today at €228.05 after investors digested a newly announced €5.5 billion settlement covering approximately 76,000...
Johnson & Johnson Announces $5.5 Billion Settlement to Resolve Talc Lawsuits
Johnson & Johnson has agreed to pay an estimated $5.5 billion to resolve tens of thousands of lawsuits alleging its talc-based products, including its iconic...
J&J wins key ruling in 69,000 lawsuits, judge doubts scientific evidence
A New Jersey federal judge questioned the scientific evidence in approximately 69,000 lawsuits against Johnson & Johnson. The plaintiffs allege the company's...
J&J Myeloma Combo Slashes Progression Risk 89%, Signaling New Care Standard
Johnson & Johnson reported Phase 3 MonumenTAL-6 study results for multiple myeloma treatment. The combination of bispecific antibodies Tecvayli and Talvey...
J&J's Surgical Robot Gets the Green Light — But Can It Actually Dent Intuitive Surgical's Dominance?
Shares of Johnson & Johnson edged up just 0.1% to $220.40 on news that the FDA cleared its long-awaited robotic surgery system for general procedures — a muted...
J&J Wins FDA Clearance for OTTAVA Robot to Rival Intuitive Surgical
Johnson & Johnson received U.S. FDA De Novo marketing authorization for its OTTAVA Robotic Surgical System. The system is cleared for general surgery...
Johnson & Johnson moves to dismiss 67,000 talc lawsuits, citing missing experts
Johnson & Johnson petitioned a federal judge to dismiss 67,000 lawsuits alleging its talc-based products cause ovarian cancer. These cases are currently...
J&J raises forecast as drug sales offset Abiomed heart pump slump
Johnson & Johnson raised its full-year forecast after exceeding second-quarter Wall Street expectations. The company reported $25.3 billion in revenue....
Johnson & Johnson Recalls Impella Heart Pumps, Citing Undetectable Leak Risks
Johnson & Johnson subsidiary Abiomed, Inc. is recalling the ABIOMED Impella CP heart pump set. The FDA designated this as a Class 1 recall, which is the most...
Johnson & Johnson Wins FDA Approval for Dual-Energy Heart Ablation Platform
Johnson & Johnson received FDA approval for its Dual Energy THERMOCOOL SMARTTOUCH SF Platform on July 8, 2026. The integrated catheter ablation solution...
🟢 JNJ.DE climbs 3.7% on MedTech launch and pharma pipeline strength
JNJ.DE is trading 3.7% up at $218.60, fueled by the commercial launch of its Dual Energy THERMOCOOL SMARTTOUCH SF Platform in Europe today. The rally is...
🟢 JNJ.DE is trading 0.9% up today amid positive clinical data and increased institutional interest
• Johnson & Johnson has seen positive mid-June clinical and product updates, including strong TALVEY combination data in multiple myeloma and positive Phase...
Johnson & Johnson TRUFILL cuts brain bleed recurrence risk by 47%
Johnson & Johnson published primary results from the MEMBRANE randomized controlled trial in JAMA Neurology on June 19, 2026. The study evaluated middle...
Johnson & Johnson invests $1B in Florida, scaling ACUVUE contact lens production
Johnson & Johnson is investing over $1 billion to expand its vision care operations in Jacksonville, Florida. The project scales domestic manufacturing and...